Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

被引:4
作者
Godfrey, Hannah [1 ]
Leibovit-Reiben, Zachary [1 ]
Jedlowski, Patrick [2 ]
Thiede, Rebecca [2 ]
机构
[1] Univ Arizona, Coll Med Tucson, 1501 N Campbell Ave, Tucson, AZ 85724 USA
[2] Univ Arizona, Div Dermatol, Coll Med Tucson, Tucson, AZ USA
关键词
RECEPTOR;
D O I
10.1111/jdv.20197
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页码:e153 / e154
页数:2
相关论文
共 9 条
  • [1] National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
    Adhikari, Rishav
    Jha, Kunal
    Dardari, Zeina
    Heyward, James
    Blumenthal, Roger S.
    Eckel, Robert H.
    Alexander, G. Caleb
    Blaha, Michael J.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (09):
  • [2] Medication-induced hair loss: An update
    Alhanshali, Lina
    Buontempo, Michael
    Shapiro, Jerry
    Lo Sicco, Kristen
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : S20 - S28
  • [3] Bariatric Surgery-Induced Telogen Effluvium (Bar SITE): Case Report and a Review of Hair Loss Following Weight Loss Surgery
    Cohen-Kurzrock, Rena A.
    Cohen, Philip R.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [4] Case non-case studies: Principle, methods, bias and interpretation
    Faillie, Jean-Luc
    [J]. THERAPIE, 2019, 74 (02): : 225 - 232
  • [5] FDA Internet, 2024, RES C JULY SEPTEMBER
  • [6] Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin
    List, James F.
    He, Huile
    Habener, Joel F.
    [J]. REGULATORY PEPTIDES, 2006, 134 (2-3) : 149 - 157
  • [7] Commonly prescribed medications associated with alopecia
    Mounessa, Jessica
    V. Caravaglio, Joseph
    Domozych, Renee
    Chapman, Stephanie
    Dellavalle, Robert P.
    Dunnick, Cory A.
    Norris, David
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (06) : 1326 - +
  • [8] Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
    O'Neil, Patrick M.
    Birkenfeld, Andreas L.
    McGowan, Barbara
    Mosenzon, Ofri
    Pedersen, Sue D.
    Wharton, Sean
    Carson, Charlotte Giwercman
    Jepsen, Cecilie Heerdegen
    Kabisch, Maria
    Wilding, John P. H.
    [J]. LANCET, 2018, 392 (10148) : 637 - 649
  • [9] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    [J]. LANCET, 2021, 398 (10295) : 143 - 155